Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas

References

• Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans HC, Boerma EJ, Kluin PM. Double-hit B-cell lymphomas. Blood 2010; 117:2319-31; PMID:21119107; http://dx.doi.org/10.1182/blood-2010-09-297879
   PubMed Web of Science ®Google Scholar
• Le Gouill S, Talmant P, Touzeau C, Moreau A, Garand R, Juge-Morineau N, Gaillard F, Gastinne T, Milpied N, Moreau P, et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica 2007; 92:1335-42; PMID:18024371; http://dx.doi.org/10.3324/haematol.11305
   PubMed Web of Science ®Google Scholar
• Niitsu N, Okamoto M, Miura I, Hirano M. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia 2009; 23:777-83; PMID:19151788; http://dx.doi.org/10.1038/leu.2008.344
   PubMed Web of Science ®Google Scholar
• Tomita N, Tokunaka M, Nakamura N, Takeuchi K, Koike J, Motomura S, Miyamoto K, Kikuchi A, Hyo R, Yakushijin Y, et al. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica 2009; 94:935-43; PMID:19535347; http://dx.doi.org/10.3324/haematol.2008.005355
   PubMed Web of Science ®Google Scholar
• Snuderl M, Kolman OK, Chen YB, Hsu JJ, Ackerman AM, Dal Cin P, Ferry JA, Lee Harris N, Hasserjian RP, Zukerberg LR, et al. B-cell Lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol 2010; 34:327-40; PMID:20118770; http://dx.doi.org/10.1097/PAS.0b013e3181cd3aeb
   PubMed Web of Science ®Google Scholar
• Barrans S, Crouch S, Smith A, Turner K, Owen R, Patmore R, Roman E, Jack A. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-Cell Lymphoma treated in the era of rituximab. J Clin Oncol 2010; 28:3360-5; PMID:20498406; http://dx.doi.org/10.1200/JCO.2009.26.3947
   PubMed Web of Science ®Google Scholar
• Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P, Horsman DE, Gascoyne RD. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009; 114:3533-7; PMID:19704118; http://dx.doi.org/10.1182/blood-2009-05-220095
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, et al. The 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms. Blood 2016; 127:2391-405; PMID:27069254; http://dx.doi.org/10.1182/blood-2016-01-643569
   PubMed Web of Science ®Google Scholar
• Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood 2014; 124:2354-61; PMID:25161267; http://dx.doi.org/10.1182/blood-2014-05-578963
   PubMed Web of Science ®Google Scholar
• Aukema SM, Kreuz M, Kohler CW, Rosolowski M, Hasenclever D, Hummel M, Küppers R, Lenze D, Ott G, Pott C, et al. Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica 2014; 99:726-35; PMID:24179151; http://dx.doi.org/10.3324/haematol.2013.091827
   PubMed Web of Science ®Google Scholar
• Iqbal J, Meyer PN, Smith LM, Johnson NA, Vose JM, Greiner TC, Connors JM, Staudt LM, Rimsza L, Jaffe E, et al. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Clin Cancer Res 2011; 17:7785-95; PMID:21933893; http://dx.doi.org/10.1158/1078-0432.CCR-11-0267
   PubMed Web of Science ®Google Scholar
• Johnson NA, Savage KJ, Ludkovski O, Ben-Neriah S, Woods R, Steidl C, Dyer MJ, Siebert R, Kuruvilla J, Klasa R, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009; 114:2273-9; PMID:19597184; http://dx.doi.org/10.1182/blood-2009-03-212191
   PubMed Web of Science ®Google Scholar
• Pedersen MØ, Gang AO, Poulsen TS, Knudsen H, Lauritzen AF, Nielsen SL, Klausen TW, Nørgaard P. MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations. Eur J Haematol 2014; 92:42-8; PMID:24118498; http://dx.doi.org/10.1111/ejh.12212
   PubMed Web of Science ®Google Scholar
• Valera A, López-Guillermo A, Cardesa-Salzmann T, Climent F, González-Barca E, Mercadal S, Espinosa Í, Novelli S, Briones J, Mate JL, et al. MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica 2013; 98:1554-62; PMID:23716551; http://dx.doi.org/10.3324/haematol.2013.086173
   PubMed Web of Science ®Google Scholar
• Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC, Klapper W, Hummel M, Stein H, Hansmann ML, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 2013; 121:2253-63; PMID:23335369; http://dx.doi.org/10.1182/blood-2012-06-435842
   PubMed Web of Science ®Google Scholar
• Wang W, Hu S, Lu X, Young KH, Medeiros LJ. Triple-hit B-cell lymphoma with MYC, BCL2, and BCL6 translocations/rearrangements: Clinicopathologic Features of 11 Cases. Am J Surg Pathol 2015; 39:1132-9; PMID:25828391; http://dx.doi.org/10.1097/PAS.0000000000000434
   PubMed Web of Science ®Google Scholar
• Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, Liu W, Visco C, Li Y, Miranda RN, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the international DLBCL Rituximab-CHOP consortium program. Blood 2013; 121:4021-31; PMID:23449635; http://dx.doi.org/10.1182/blood-2012-10-460063
   PubMed Web of Science ®Google Scholar
• Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, Scott DW, Tan KL, Steidl C, Sehn LH, et al. Concurrent Expression of MYC and BCL2 in diffuse large B-Cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012; 30:3452-9; PMID:22851565; http://dx.doi.org/10.1200/JCO.2011.41.0985
   PubMed Web of Science ®Google Scholar
• Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, Nielsen O, Gadeberg OV, Mourits-Andersen T, Frederiksen M, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-Cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012; 30:3460-7; PMID:22665537; http://dx.doi.org/10.1200/JCO.2011.41.4342
   PubMed Web of Science ®Google Scholar
• Karube K, Campo E. MYC alterations in diffuse large B-Cell lymphomas. Semin Hematol 2015; 52:97-106; PMID:25805589; http://dx.doi.org/10.1053/j.seminhematol.2015.01.009
   PubMed Web of Science ®Google Scholar
• Swerdlow SH. Diagnosis of “double hit” diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC. ASH Educ Progr B 2014; 2014:90-9
   Google Scholar
• Sarkozy C, Traverse-Glehen A, Coiffier B. Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas. Lancet Oncol [ Internet] 2016; 16:e555-67; http://dx.doi.org/10.1016/S1470-2045(15)00005-4
   Google Scholar
• Sabo A, Kress TR, Pelizzola M, de Pretis S, Gorski MM, Tesi A, Morelli MJ, Bora P, Doni M, Verrecchia A, et al. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature 2014; 511:488-92; PMID:25043028; http://dx.doi.org/10.1038/nature13537
   PubMed Web of Science ®Google Scholar
• Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 2004; 432:635-9; PMID:15577913; http://dx.doi.org/10.1038/nature03147
   PubMed Web of Science ®Google Scholar
• Ranuncolo SM, Polo JM, Melnick A. BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells. Blood Cells, Mol Dis 2008; 41:95-9; http://dx.doi.org/10.1016/j.bcmd.2008.02.003
   PubMed Web of Science ®Google Scholar
• Ranuncolo SM, Polo JM, Dierov J, Singer M, Kuo T, Greally J, Green R, Carroll M, Melnick A. Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat Immunol 2007; 8:705-14; PMID:17558410; http://dx.doi.org/10.1038/ni1478
   PubMed Web of Science ®Google Scholar
• Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 2005; 6:635-45; PMID:16064138; http://dx.doi.org/10.1038/nrm1703
   PubMed Web of Science ®Google Scholar
• Yin X, Giap C, Lazo JS, Prochownik EV. Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 2003; 22:6151-9; PMID:13679853; http://dx.doi.org/10.1038/sj.onc.1206641
   PubMed Web of Science ®Google Scholar
• Huang MJ, Cheng Y, Liu CR, Lin S, Liu HE. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp Hematol 2006; 34:1480-9; PMID:17046567; http://dx.doi.org/10.1016/j.exphem.2006.06.019
   PubMed Web of Science ®Google Scholar
• Holien T, Misund K, Olsen OE, Baranowska KA, Buene G, Børset M, Waage A, Sundan A. MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy. Oncotarget 2015; 6:22698-705; PMID:26087190; http://dx.doi.org/10.18632/oncotarget.4245
   PubMed Web of Science ®Google Scholar
• Guo J, Parise RA, Joseph E, Egorin MJ, Lazo JS, Prochownik EV, Eiseman JL. Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc–Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemother Pharmacol 2009; 63:615-25; PMID:18509642; http://dx.doi.org/10.1007/s00280-008-0774-y
   PubMed Web of Science ®Google Scholar
• Ahmad KF, Melnick A, Lax S, Bouchard D, Liu J, Kiang C-L, Mayer S, Takahashi S, Licht JD, Privé GG. Mechanism of SMRT Corepressor recruitment by the BCL6 BTB domain. Mol Cell 2003; 12:1551-64; PMID:14690607; http://dx.doi.org/10.1016/S1097-2765(03)00454-4
   PubMed Web of Science ®Google Scholar
• Cerchietti LC, Yang SN, Shaknovich R, Hatzi K, Polo JM, Chadburn A, Dowdy SF, Melnick A. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood 2008; 113:3397-405; PMID:18927431; http://dx.doi.org/10.1182/blood-2008-07-168773
   PubMed Web of Science ®Google Scholar
• Cerchietti LC, Ghetu AF, Zhu X, Da Silva GF, Zhong S, Matthews M, Bunting KL, Polo JM, Farès C, Arrowsmith CH, et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell 2010; 17:400-11; PMID:20385364; http://dx.doi.org/10.1016/j.ccr.2009.12.050
   PubMed Web of Science ®Google Scholar
• Cardenas M, Yu W, Beguelin W, Teater M, Geng H, Goldstein R, Oswald E, Hatzi K, Yang SN, Cohen J, et al. Therapeutic targeting of GCB- and ABC-DLBCLs by rationally designed BCL6 inhibitors. J Clin Invest 2016; 126(9); http://dx.doi.org/10.1172/JCI85795
   PubMedGoogle Scholar
• Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014; 15:49-63; PMID:24355989; http://dx.doi.org/10.1038/nrm3722
   PubMed Web of Science ®Google Scholar
• Llambi F, Moldoveanu T, Tait SW, Bouchier-Hayes L, Temirov J, McCormick LL, Dillon CP, Green DR. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol Cell 2011; 44:517-31; PMID:22036586; http://dx.doi.org/10.1016/j.molcel.2011.10.001
   PubMed Web of Science ®Google Scholar
• Anderson MA, Huang D, Roberts A. Targeting BCL2 for the treatment of lymphoid malignancies. Semin Hematol 2014; 51:219-27; PMID:25048785; http://dx.doi.org/10.1053/j.seminhematol.2014.05.008
   PubMed Web of Science ®Google Scholar
• Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM, Huang DC. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17:393-403; PMID:15694340; http://dx.doi.org/10.1016/j.molcel.2004.12.030
   PubMed Web of Science ®Google Scholar
• Vela L, Marzo I. Bcl-2 family of proteins as drug targets for cancer chemotherapy: the long way of BH3 mimetics from bench to bedside. Curr Opin Pharmacol 2015; 23:74-81; PMID:26079328; http://dx.doi.org/10.1016/j.coph.2015.05.014
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, Puvvada SD, Wendtner CM, Roberts AW, Jurczak W, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol 2016; 17:768-78; PMID:27178240; http://dx.doi.org/10.1016/S1470-2045(16)30019-5
   PubMed Web of Science ®Google Scholar
• Sasaki N, Kuroda J, Nagoshi H, Yamamoto M, Kobayashi S, Tsutsumi Y, Kobayashi T, Shimura Y, Matsumoto Y, Taki T, et al. Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression. Exp Hematol 2011; 39:817-28.e1; PMID:21640157; http://dx.doi.org/10.1016/j.exphem.2011.05.002
   PubMed Web of Science ®Google Scholar
• Cinar M, Rosenfelt F, Rokhsar S, Lopategui J, Pillai R, Cervania M, Pao A, Cinar B, Alkan S. Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas. Leuk Res 2015; 39:730-8; PMID:25916698; http://dx.doi.org/10.1016/j.leukres.2015.04.003
   PubMed Web of Science ®Google Scholar
• Dupont T, Yang S, Patel J, Hatzi K, Malik A, Tam W, Martin P, Leonard J, Melnick A, Cerchietti L. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma. Oncotarget 2016; 7:3520-32; PMID:26657288
   PubMed Web of Science ®Google Scholar
• Berdasco M, Esteller M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell 2010; 19:698-711; PMID:21074720; http://dx.doi.org/10.1016/j.devcel.2010.10.005
   PubMed Web of Science ®Google Scholar
• De S, Shaknovich R, Riester M, Elemento O, Geng H, Kormaksson M, Jiang Y, Woolcock B, Johnson N, Polo JM, et al. Aberration in DNA methylation in B-Cell lymphomas has a complex origin and increases with disease severity. PLoS Genet 2013; 9:e1003137; PMID:23326238; http://dx.doi.org/10.1371/journal.pgen.1003137
   PubMedGoogle Scholar
• Shaknovich R, De S, Michor F. Epigenetic diversity in hematopoietic neoplasms. Biochim Biophys Acta - Rev Cancer 2014; 1846:477-84; http://dx.doi.org/10.1016/j.bbcan.2014.09.003
   PubMed Web of Science ®Google Scholar
• Clozel T, Yang S, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW, et al. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-Cell lymphoma. Cancer Discov 2013; 3:1002-19; PMID:23955273; http://dx.doi.org/10.1158/2159-8290.CD-13-0117
   PubMed Web of Science ®Google Scholar
• Pera B, Cerchietti L. Personalized Epigenetic Therapy - Chemosensitivity testing. In: Gray S, editor. Epigenetic Cancer Therapy 2015; 28:667-76; http://dx.doi.org/10.1016/B978-0-12-800206-3.00028-8
   Google Scholar
• Lai AY, Fatemi M, Dhasarathy A, Malone C, Sobol SE, Geigerman C, Jaye DL, Mav D, Shah R, Li L, et al. DNA methylation prevents CTCF-mediated silencing of the oncogene BCL6 in B cell lymphomas. J Exp Med 2010; 207:1939-50; PMID:20733034; http://dx.doi.org/10.1084/jem.20100204
   PubMed Web of Science ®Google Scholar
• Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, Gomes Da Gama EM, Caldas-Lopes E, Beebe K, Perna F, Hatzi K, et al. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol 2011; 7:818-26; PMID:21946277; http://dx.doi.org/10.1038/nchembio.670
   PubMed Web of Science ®Google Scholar
• Zappasodi R, Bongarzone I, Ghedini GC, Castagnoli L, Cabras AD, Messina A, Tortoreto M, Tripodo C, Magni M, Carlo-Stella C, et al. Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target. Blood 2011; 118:4421-30; PMID:21860023; http://dx.doi.org/10.1182/blood-2011-06-364570
   PubMed Web of Science ®Google Scholar
• Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, Zhang T, Hatheway CM, Abraham BJ, Sharma B, Yeung C, Altabef A, et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-Driven cancer. Cell 2014; 159:1126-39; PMID:25416950; http://dx.doi.org/10.1016/j.cell.2014.10.024
   PubMed Web of Science ®Google Scholar
• Chapuy B, McKeown MR, Lin CY, Monti S, Roemer MG, Qi J, Rahl PB, Sun HH, Yeda KT, Doench JG, et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B Cell lymphoma. Cancer Cell 2013; 24:777-90; PMID:24332044; http://dx.doi.org/10.1016/j.ccr.2013.11.003
   PubMed Web of Science ®Google Scholar
• Marullo R, Yang S, Rashal T, Landesman Y, Carlson R, Shacham S, Cerchietti LC. Abstract LB-062: XPO1 is a rational target for double and triple-hit aggressive B-cell lymphomas. Cancer Res 2015; 75:LB - 062 - LB - 062; http://dx.doi.org/10.1158/1538-7445.AM2015-LB-062
   Google Scholar
• Stade K, Ford CS, Guthrie C, Weis K. Exportin 1 (Crm1p) is an essential nuclear export factor. Cell 1997; 90:1041-50; PMID:9323132; http://dx.doi.org/10.1016/S0092-8674(00)80370-0
   PubMed Web of Science ®Google Scholar
• Neggers JE, Vercruysse T, Jacquemyn M, Vanstreels E, Baloglu E, Shacham S, Crochiere M, Landesman Y, Daelemans D. Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing. Chem Biol 2015; 22:107-16; PMID:25579209; http://dx.doi.org/10.1016/j.chembiol.2014.11.015
   PubMed Web of Science ®Google Scholar
• Ruggero D, Montanaro L, Ma L, Xu W, Londei P, Cordon-Cardo C, Pandolfi PP. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004; 10:484-6; PMID:15098029; http://dx.doi.org/10.1038/nm1042
   PubMed Web of Science ®Google Scholar
• Truitt ML, Conn CS, Shi Z, Pang X, Tokuyasu T, Coady AM, Seo Y, Barna M, Ruggero D. Differential requirements for eIF4E dose in normal development and cancer. Cell 2015; 162:59-71; PMID:26095252; http://dx.doi.org/10.1016/j.cell.2015.05.049
   PubMed Web of Science ®Google Scholar
• Culjkovic-Kraljacic B, Baguet A, Volpon L, Amri A, Borden KL. The Oncogene eIF4E Reprograms the nuclear pore complex to promote mRNA export and oncogenic transformation. Cell Rep 2012; 2:207-15; PMID:22902403; http://dx.doi.org/10.1016/j.celrep.2012.07.007
   PubMed Web of Science ®Google Scholar
• Kentsis A, Topisirovic I, Culjkovic B, Shao L, Borden KLB. Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci 2004; 101:18105-10; PMID:15601771; http://dx.doi.org/10.1073/pnas.0406927102
   PubMed Web of Science ®Google Scholar
• Assouline S, Culjkovic-Kraljacic B, Bergeron J, Caplan S, Cocolakis E, Lambert C, Lau CJ, Zahreddine HA, Miller WH, Borden KL. A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E. Haematologica 2015; 100:e7-9; PMID:25425688; http://dx.doi.org/10.3324/haematol.2014.111245
   PubMed Web of Science ®Google Scholar
• Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, Caplan S, Leber B, Roy DC, Miller WH, et al. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood 2009; 114:257-60; PMID:19433856; http://dx.doi.org/10.1182/blood-2009-02-205153
   PubMed Web of Science ®Google Scholar
• Culjkovic-Kraljacic B, Fernando TM, Marullo R, Calvo-Vidal N, Verma A, Yang S, Tabb∫ F, Gaudiano M, Zahreddine H, Goldstein RL, et al. Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas. Blood 2015; 127:858-68; PMID:26603836; http://dx.doi.org/10.1182/blood-2015-05-645069
   PubMed Web of Science ®Google Scholar
• Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010; 10:537-49; PMID:20651736; http://dx.doi.org/10.1038/nrc2887
   PubMed Web of Science ®Google Scholar
• Taldone T, Ochiana SO, Patel PD, Chiosis G. Selective targeting of the stress chaperome as a therapeutic strategy. Trends Pharmacol Sci 2014; 35:592-603; PMID:25262919; http://dx.doi.org/10.1016/j.tips.2014.09.001
   PubMed Web of Science ®Google Scholar
• Goldstein RL, Yang SN, Taldone T, Chang B, Gerecitano J, Elenitoba-Johnson K, Shaknovich R, Tam W, Leonard JP, Chiosis G, et al. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma. J Clin Invest 2015; 125:4559-71; PMID:26529251; http://dx.doi.org/10.1172/JCI80714
   PubMed Web of Science ®Google Scholar
• Cerchietti LC, Lopes EC, Yang SN, Hatzi K, Bunting KL, Tsikitas LA, Mallik A, Robles AI, Walling J, Varticovski L, et al. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat Med 2009; 15:1369-76; PMID:19966776; http://dx.doi.org/10.1038/nm.2059
   PubMed Web of Science ®Google Scholar